Dermaceum Sp. z o.o. — Clinical Trial Site

11 Registered trials

7 Currently recruiting

Organisation

Dermaceum Sp. z o.o.

Location

Wroclaw, Poland

Identifier

ORG-100054217

Address

Ul. Zygmunta Krasinskiego 29, 50-449, Poland

Departments

#45008:DERMACEUM Centrum Medyczne
DERMACEUM CENTRUM MEDYCZNE
Dermatology
POL05421: Dermatology

Clinical trials at this site (11)

Search interface

Dose-finding study of LAD603 in adults with alopecia areata Recruiting

2025-523342-27-00 Alopecia areata 4 2026-04-10
A first-in-human, open-label, dose finding study to evaluate the safety, tolerability and pharmacokinetics of EGL-003 in healthy volunteers … Recruiting

2025-521658-40-00 Atopic dermatitis 1 2025-10-27
A Study to Evaluate the Long-term Safety and Effectiveness of APG777 in Subjects with Atopic Dermatitis Recruiting

2024-519795-11-00 Atopic Dermatitis 4 2025-10-06
A Phase 2 Study of Lesigercept (YH35324) in Adult Patients with Chronic Spontaneous Urticaria (CLEAR) Recruiting

2025-524006-14-00 Chronic Spontaneous Urticaria 4 2026-04-20
Phase 3 Efficacy and Safety of Lebrikizumab in Adults With Nummular Eczema (LUMINE) Recruiting

2025-522403-17-00 Nummular Dermatitis 5 2026-04-10
A study to learn if galvokimig is safe and works in adults with moderate to severe atopic dermatitis Recruiting

2025-522578-35-00 Atopic Dermatitis 4 2026-03-30
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Daily Piclidenoson (CF101) Administered Orally i… Recruiting

2024-519919-34-00 Plaque psoriasis 5 2025-08-18
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients with Prurigo No… Ended

2023-510279-80-00 Prurigo nodularis 4 2024-09-25
A Study to Evaluate the Safety and Effectiveness of APG777 in Subjects with Atopic Dermatitis Ended

2024-511260-84-00 Atopic Dermatitis 4 2024-09-03
A Study of the Efficacy and Safety of Brensocatib in Adults with Moderate to Severe Hidradenitis Suppurativa Ended

2024-515959-38-00 Hidradenitis Suppurativa 4 2025-03-06
Phase 3, 52-week Study Evaluating Rocatinlimab (AMG451)in Adolescent Subjects With Moderate-to-severe AD (ROCKET-ASTRO) Ended

2022-501586-50-00 Atopic Dermatitis 5 2023-05-15